LL-37 · Research brief

Is LL-37 Better Than Cathelicidin? (Mechanism Explained)

Real Peptides Research TeamEditorial

Updated June 9, 20268 min read

46 WORDS

Short answer

Key takeaways

LL-37 is the 37-amino-acid bioactive fragment cleaved from the 134-residue cathelicidin precursor protein hCAP-18. Not a competing molecule.
hCAP-18 has no antimicrobial or immunomodulatory activity until proteinase 3 or tissue kallikreins remove the N-terminal cathelin domain.
LL-37 adopts an amphipathic alpha-helical structure that allows membrane insertion and lipid bilayer disruption, conferring activity against bacteria, fungi, and enveloped viruses.
Minimum inhibitory concentrations for LL-37 range from 2–8 micrograms per milliliter against common pathogens, while uncleaved hCAP-18 shows no measurable antimicrobial effect.
Dysregulation of the cleavage pathway. Either overproduction (rosacea) or deficient processing (Morbus Kostmann). Causes distinct clinical pathologies despite normal precursor expression.
Research applications require synthetic LL-37 because intact cathelicidin must undergo enzymatic processing to generate functional peptide.

Most questions about whether LL-37 is 'better than' cathelicidin stem from a fundamental misunderstanding of peptide biochemistry. LL-37 is not an alternative to cathelicidin. It is the functional product derived from the inactive precursor protein hCAP-18 (human cationic antimicrobial protein), which researchers refer to as cathelicidin. When proteinase 3 cleaves the 103-residue propeptide domain from hCAP-18 during neutrophil activation, the remaining 37-amino-acid C-terminal fragment becomes LL-37, named for its two N-terminal leucine residues. The question isn't which is superior. It's understanding that one is the precursor and the other is the active form that performs antimicrobial and immunomodulatory functions throughout the body.

Our team works directly with laboratories conducting peptide research across immune function, wound healing, and antimicrobial applications. The distinction between hCAP-18 and LL-37 matters operationally because only the cleaved, active LL-37 fragment exhibits the biological activity researchers seek. The intact cathelicidin precursor does not.

Is LL-37 better than cathelicidin?

LL-37 is not 'better than' cathelicidin. It is the 37-amino-acid bioactive fragment cleaved from the cathelicidin precursor protein hCAP-18. Cathelicidin refers to the entire gene family and the inactive propeptide; LL-37 is the functional antimicrobial peptide released after enzymatic cleavage by proteinase 3. The parent protein hCAP-18 has no antimicrobial activity until converted into LL-37 through neutrophil degranulation or epithelial cell processing.

The Direct Answer: LL-37 Is the Active Form of Cathelicidin

The confusion arises because 'cathelicidin' is both a gene family name and shorthand for the precursor protein. Human cathelicidin. Encoded by the CAMP gene. Produces hCAP-18, an 18-kilodalton protein stored in neutrophil granules and epithelial cells. hCAP-18 remains inactive until proteolytic cleavage by proteinase 3 (in neutrophils) or kallikreins (in epithelial tissue) releases the C-terminal 37-residue peptide LL-37. That cleaved fragment is what performs antimicrobial killing, modulates inflammation, recruits immune cells, and promotes angiogenesis. This article covers the enzymatic conversion pathway, the structural differences that confer activity, and what the distinction means for laboratory applications and supplementation claims.

hCAP-18 Versus LL-37: Structural and Functional Distinctions

hCAP-18 is a 134-amino-acid precursor protein with two domains: the conserved cathelin-like domain (residues 1–97) and the C-terminal antimicrobial domain (residues 98–134, which becomes LL-37 after cleavage). The cathelin domain stabilizes the molecule during storage but contributes no antimicrobial activity. When neutrophils degranulate during infection or tissue damage, serine protease 3 cleaves the bond between residues 97 and 98, releasing LL-37 into the extracellular environment. The released peptide adopts an alpha-helical conformation in membrane-mimetic environments, allowing it to insert into bacterial membranes and disrupt lipid bilayers. The primary mechanism behind its broad-spectrum antimicrobial activity against gram-positive bacteria, gram-negative bacteria, fungi, and enveloped viruses.

The structural shift from linear precursor to amphipathic helix is what confers function. LL-37 contains both hydrophobic and cationic residues arranged so that one face of the helix interacts with negatively charged bacterial membranes while the hydrophobic face inserts into the lipid core. hCAP-18 cannot adopt this conformation while the cathelin domain remains attached. The propeptide sterically blocks membrane insertion. Research published in the Journal of Biological Chemistry demonstrated that synthetic hCAP-18 showed no antimicrobial activity against Staphylococcus aureus or Escherichia coli, while LL-37 exhibited minimum inhibitory concentrations (MIC) of 2–8 micrograms per milliliter against the same strains.

The Enzymatic Cleavage Pathway That Activates Cathelicidin

LL-37 generation occurs through distinct pathways depending on tissue type. In neutrophils, proteinase 3. Stored in azurophil granules alongside hCAP-18. Cleaves the precursor during degranulation triggered by bacterial lipopolysaccharide, cytokines, or complement activation. Epithelial cells in the respiratory tract, gastrointestinal mucosa, and skin express kallikrein proteases (KLK5, KLK7, KLK14) that process cathelicidin extracellularly after secretion. Dysregulation of this cleavage cascade underlies multiple disease states: patients with rosacea overproduce KLK5, leading to excessive LL-37 generation and chronic inflammation, while individuals with Morbus Kostmann (a severe congenital neutropenia) produce normal hCAP-18 but lack the neutrophil elastase required for processing, resulting in recurrent bacterial infections despite adequate precursor levels.

Gastricsin. An aspartic protease active at pH 2–3 in the stomach. Also cleaves hCAP-18, producing fragments distinct from LL-37 with altered antimicrobial spectra. This alternate processing generates shorter peptides (LL-29, LL-32) with reduced activity against gram-negative bacteria but enhanced fungicidal properties. The cleavage specificity explains why oral supplementation with intact cathelicidin precursors cannot replicate systemic LL-37 effects. Gastric and intestinal proteases degrade the molecule into non-functional fragments before absorption.

Comparison: hCAP-18 Precursor vs LL-37 Active Peptide

This table summarizes the functional and structural differences between the inactive cathelicidin precursor and its bioactive cleavage product.

Feature	hCAP-18 (Precursor)	LL-37 (Active Peptide)	Professional Assessment
Amino Acid Length	134 residues	37 residues	LL-37 represents only the C-terminal 28% of the precursor protein
Antimicrobial Activity	None. Cathelin domain blocks membrane insertion	Broad-spectrum: MIC 2–8 µg/mL against S. aureus, E. coli, C. albicans	Activity depends entirely on proteolytic release from the precursor
Structural Conformation	Linear with cathelin-fold N-terminus	Amphipathic alpha-helix in membrane environments	Helical structure is essential for lipid bilayer disruption
Cleavage Mechanism	Stored intact in neutrophil granules and epithelial cells	Released by proteinase 3 (neutrophils) or kallikreins (epithelia)	Cleavage is the rate-limiting step in antimicrobial response activation
Immunomodulatory Function	Minimal to none	Chemotactic for neutrophils, monocytes, T cells; modulates cytokine release	LL-37 acts as a damage-associated molecular pattern (DAMP) independent of microbial killing
Research Application Suitability	Used only as substrate in protease assays	Direct use in antimicrobial, wound healing, and immune modulation studies	Labs use synthetic LL-37 because hCAP-18 requires enzymatic processing

What If: LL-37 and Cathelicidin Scenarios

What If I See Products Labeled 'Cathelicidin Supplements' — Are They Effective?

Avoid them. Oral cathelicidin supplements contain either hCAP-18 precursor protein or bovine-derived cathelicidin analogues, neither of which survives gastric digestion intact. Pepsin and gastricsin in the stomach cleave the peptide into fragments with no antimicrobial activity, and intestinal proteases further degrade any remaining structure before absorption. No published pharmacokinetic study has demonstrated detectable plasma LL-37 elevation after oral hCAP-18 administration. The bioactive LL-37 peptide itself would also be degraded orally. Functional delivery requires parenteral administration or topical application to intact epithelial barriers.

What If Research Protocols Call for 'Cathelicidin' — Which Form Should Be Used?

Use synthetic LL-37 unless the study specifically investigates proteolytic processing or precursor biology. When researchers refer to 'cathelicidin' in antimicrobial or immunomodulation assays, they mean the active LL-37 fragment. Not the hCAP-18 precursor. Real Peptides supplies research-grade LL-37 with validated sequence fidelity and endotoxin testing, eliminating the variability introduced by enzymatic cleavage steps. If your protocol requires physiologically relevant activation kinetics, you'll need both recombinant hCAP-18 and purified proteinase 3, but most functional assays bypass the precursor entirely.

What If Endogenous LL-37 Levels Are Low — Can Supplementation or Activation Strategies Help?

Systemic LL-37 deficiency occurs in specific genetic conditions (Morbus Kostmann) or acquired states (vitamin D deficiency, chronic malnutrition). Vitamin D upregulates CAMP gene transcription, increasing hCAP-18 production. Clinical trials showed 25-hydroxyvitamin D supplementation raised plasma cathelicidin levels by 40–80% in deficient individuals. Direct LL-37 supplementation for systemic immune support remains experimental; most therapeutic applications focus on topical wound-healing formulations or aerosolized delivery for respiratory infections. No FDA-approved LL-37 drug product exists as of 2026, though Phase II trials are ongoing for chronic wound management.

The Blunt Truth About 'LL-37 vs Cathelicidin' Marketing

Here's the honest answer: any product claiming LL-37 is 'superior to cathelicidin' or positioning them as competing options is either scientifically illiterate or deliberately misleading. They are not alternatives. LL-37 is the functional form of cathelicidin. It's like asking whether insulin is better than proinsulin: one is the inactive precursor, the other is what your body uses. The confusion is profitable for supplement companies selling 'cathelicidin activators' or 'precursor support formulas' with no evidence of efficacy. If you're evaluating a product that treats these as separate entities, you're looking at marketing, not biochemistry. For research purposes, the distinction matters operationally: labs order synthetic LL-37 because the precursor requires enzymatic processing before it does anything useful.

Why the Precursor-to-Product Relationship Matters for Research Applications

The enzymatic activation requirement creates experimental constraints researchers must account for. In vitro antimicrobial assays using cell-free systems require pre-cleaved LL-37. Adding hCAP-18 without proteinase 3 produces false-negative results because no active peptide forms. Conversely, studies investigating endogenous antimicrobial peptide responses in whole blood or tissue explants must measure both precursor and product to distinguish synthesis defects from cleavage defects. Patients with chronic granulomatous disease produce normal hCAP-18 but show impaired LL-37 generation due to defective neutrophil oxidative burst, which indirectly affects proteinase 3 release. Measuring only total cathelicidin misses the functional deficit.

Our team has observed this distinction matter significantly in wound-healing research. Chronic diabetic ulcers show elevated hCAP-18 in wound fluid but reduced LL-37, indicating a processing failure rather than synthesis failure. Topical application of synthetic LL-37 accelerated re-epithelialization in these wounds, while hCAP-18 application had no effect. The local protease environment was insufficient to activate the precursor. This finding underscores why therapeutic development focuses on the active peptide rather than precursor augmentation strategies. When selecting peptides for laboratory work, understanding whether your experimental question targets synthesis, cleavage, or effector function determines which molecular form you need. The full peptide collection at Real Peptides includes sequence-verified LL-37 designed specifically for functional assays where bioactivity must be immediate and independent of enzymatic processing.

Asking whether LL-37 is better than cathelicidin reflects confusion about the activation cascade, not a meaningful comparison between competing molecules. The precursor has one function: serving as a stable storage form until proteolytic cleavage releases the peptide that performs the immune work. For any application requiring antimicrobial activity, immunomodulation, or wound repair, LL-37 is the form that matters. The precursor is simply how the body keeps it inactive until needed.

References

Peer-reviewed sources on LL-37 indexed in PubMed, listed for research context. Real Peptides supplies LL-37 for laboratory research use only.

Cathelicidin LL-37-ApoB-100 interaction promotes LDL clearance and attenuates cholesterol accumulation in the liver. Science China. Life sciences, 2026. PMID 40971038. doi:10.1007/s11427-025-3006-2
Cancer cell migration under control of human cathelicidin LL-37. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2026. PMID 41916132. doi:10.1016/j.biopha.2026.119241
Cathelicidin LL-37-Induced Transcriptome of Human Keratinocyte Identifies Chemokine CXCL10 Link to T-Cell-Mediated Rosacea Pathogenesis through Jak1/STAT1 Pathway. The Journal of investigative dermatology, 2026. PMID 40835085. doi:10.1016/j.jid.2025.08.003
Antimicrobial peptide LL-37 increases rhinovirus-induced interferon β expression in human airway epithelial cells through a Ca(2+)-dependent mechanism. Biochemistry and biophysics reports, 2025. PMID 40612001. doi:10.1016/j.bbrep.2025.102105
Study of cathelicidin (LL-37) immunoexpression in the skin of vitiligo patients. Archives of dermatological research, 2025. PMID 39873762. doi:10.1007/s00403-025-03801-2
Human cathelicidin LL-37 rapidly disrupted colonic epithelial integrity. Biochimica et biophysica acta. Biomembranes, 2025. PMID 39837472. doi:10.1016/j.bbamem.2025.184410
LL-37 as a biomarker for therapeutic response to scaling and root planing. Journal of Indian Society of Periodontology, 2025. PMID 41438788. doi:10.4103/jisp.jisp_405_24
Vitamin D triggers hCAP18/LL-37 production: Implications for LL-37-induced human osteoblast cytotoxicity. Biochemical and biophysical research communications, 2024. PMID 38642493. doi:10.1016/j.bbrc.2024.149962

Questions

LL-37 is the 37-amino-acid bioactive fragment derived from the cathelicidin precursor protein hCAP-18. ‘Cathelicidin’ refers to both the gene family (CAMP gene) and the inactive 134-residue precursor stored in immune cells. After proteolytic cleavage by proteinase 3 or kallikreins, the C-terminal fragment becomes LL-37, the active antimicrobial peptide. They are not the same molecule — one is the inactive precursor, the other is the functional product.

The N-terminal cathelin domain (residues 1–97) in hCAP-18 sterically blocks the antimicrobial C-terminal region from adopting the amphipathic alpha-helical structure required for membrane insertion. Until proteinase 3 cleaves the bond between residues 97 and 98, the peptide cannot form the helical conformation needed to disrupt bacterial lipid bilayers. Research published in the Journal of Biological Chemistry confirmed that synthetic hCAP-18 showed zero antimicrobial activity against S. aureus or E. coli, while cleaved LL-37 exhibited MIC values of 2–8 micrograms per milliliter.

No credible evidence supports this claim. Oral cathelicidin supplements contain either hCAP-18 precursor or bovine analogues, both of which are degraded by gastric pepsin and intestinal proteases before absorption. No published pharmacokinetic study has demonstrated detectable plasma LL-37 elevation after oral hCAP-18 administration. Even synthetic LL-37 would be cleaved into inactive fragments during digestion — functional delivery requires parenteral injection or topical application to intact epithelial surfaces.

Researchers use synthetic LL-37 for any assay requiring immediate antimicrobial, immunomodulatory, or wound-healing activity because the precursor hCAP-18 must undergo enzymatic cleavage before it functions. hCAP-18 is used only in studies investigating proteolytic processing pathways, proteinase 3 kinetics, or precursor trafficking in neutrophils. When protocols refer to ‘cathelicidin’ in functional assays, they mean the active LL-37 fragment — not the intact precursor.

Morbus Kostmann (severe congenital neutropenia) patients produce normal hCAP-18 but lack functional neutrophil elastase required for processing, resulting in recurrent bacterial infections despite adequate precursor levels. Conversely, patients with rosacea overproduce tissue kallikrein 5 (KLK5), causing excessive LL-37 generation in facial skin and chronic inflammatory lesions. Chronic granulomatous disease impairs proteinase 3 release due to defective neutrophil oxidative burst, reducing LL-37 availability even when hCAP-18 synthesis is normal.

Yes — vitamin D upregulates transcription of the CAMP gene that encodes hCAP-18. Clinical trials demonstrated that 25-hydroxyvitamin D supplementation in deficient individuals raised plasma cathelicidin levels by 40–80% over 8–12 weeks. However, this increases the precursor hCAP-18, not directly LL-37; functional LL-37 generation still requires adequate proteinase 3 or kallikrein activity to cleave the precursor. Vitamin D deficiency reduces both synthesis and downstream activation, making supplementation most effective when both steps are impaired.

LL-37 exhibits MIC values of 2–8 micrograms per milliliter against gram-positive bacteria like Staphylococcus aureus, 4–16 micrograms per milliliter against gram-negative bacteria like Escherichia coli and Pseudomonas aeruginosa, and 8–32 micrograms per milliliter against Candida albicans. Activity varies with ionic strength, pH, and serum protein content — physiological salt concentrations reduce potency by up to 10-fold compared to low-salt buffer conditions used in laboratory assays.

Topical LL-37 formulations have shown efficacy in Phase II trials for chronic diabetic ulcers and venous leg ulcers, accelerating re-epithelialization and reducing bacterial burden. However, no FDA-approved LL-37 drug product exists as of 2026. Challenges include peptide stability, protease degradation at wound sites, and high manufacturing costs for synthetic peptides. Aerosolized LL-37 delivery for respiratory infections and catheter coatings to prevent biofilm formation are under investigation but remain experimental.

Chronic wounds in diabetic patients accumulate neutrophils and elevated hCAP-18 precursor, but the local protease environment is dysregulated — excess matrix metalloproteinases degrade proteinase 3 before it can cleave hCAP-18, and elevated elastase cleaves LL-37 into inactive fragments faster than it is generated. This creates a functional LL-37 deficiency despite adequate precursor synthesis. Topical synthetic LL-37 application bypasses the cleavage bottleneck and restores antimicrobial peptide activity.

Gastricsin, active in the stomach at pH 2–3, cleaves hCAP-18 at alternate sites to produce shorter fragments like LL-29 and LL-32 with altered antimicrobial spectra — reduced gram-negative activity but enhanced fungicidal properties. Kallikrein proteases in skin can generate ALL-38 (an extended form with one additional N-terminal alanine) or truncated variants depending on cleavage site specificity. These alternate products contribute to tissue-specific antimicrobial defense but are less studied than LL-37.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA